In postmenopausal women with overweight or obesity receiving tirzepatide, use of MHT is associated with superior weight loss outcomes.

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

A cutting-edge mouse study reveals that tirzepatide, the dual GLP-1/GIP drug already hailed for impressive weight loss, does more than trim fat: it slashes the growth of obesity-linked breast tumors.

Johannes Fruehauf, founder of laboratory real estate companies LabCentral and BioLabs, is increasingly looking to Europe — ...

Researchers found that pairing tirzepatide with hormone therapy boosts weight loss success in postmenopausal women—up to 17% total body weight lost.

Semaglutide, a popular anti-obesity drug, may come with a hidden cost: significant muscle loss, especially in women and older ...

U.S.-based Kailera Therapeutics and Chinese firm Jiangsu Hengrui Pharmaceuticals' experimental weight-loss drug has helped overweight patients lose up to 17.7% of body weight in a late-stage study in ...

Dear J.H.: Metformin, a treatment for diabetes that works mostly by preventing the liver from making sugar, isn't new and has ...

Metsera, Inc. (NASDAQ:MTSR) is one of the 11 Hot New Stocks to Invest in Now. On June 22, Metsera, Inc. (NASDAQ:MTSR) ...

Viking Therapeutics's obesity/diabetes candidates and strong financials position it for success. Read here for an investment ...

Major insurance changes are coming for weight loss drugs. Here’s how it could affect patients ...

When it comes to weight loss, providers and patients argue that GLP-1 medications are not a one-for-one swap and that volatile insurance coverage contradicts the science and experience of people ...